sanofi said late sunday that newly released phase 3 data on its hemophilia treatment altuviiio confirmed the drugs effectiveness and safety the french pharmaceutical company said the drug a prophylaxis approved by the us federal drug administration in february requires just one dose to prevent bleeding in children and adults children with the condition typically require injections twotofour times a week sanofi said the european medicines agency accepted the companys marketing application in may it said according to sanofi the phase 3 trials found 64 of patients had no bleeding episodes 82 had no joint bleeding and 88 had no spontaneous bleeding